Stemline Therap Drug Patent Portfolio

Stemline Therap owns 1 orange book drug protected by 8 US patents Given below is the list of Stemline Therap's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10385008 Polymorphic forms of RAD1901-2HCL 05 Jan, 2038
Active
US10745343 Polymorphic forms of RAD1901-2HCl 05 Jan, 2038
Active
US11819480 Methods for treating cancer 29 Nov, 2036
Active
US10071066 Method of treating cancer using selective estrogen receptor modulators 10 Oct, 2034
Active
US10420734 Method of treating cancer using selective estrogen receptor modulators 10 Oct, 2034
Active
US11779552 Method of treating cancer using selective estrogen receptor modulators 10 Oct, 2034
Active
US7612114 Selective estrogen receptor modulator 18 Aug, 2026
Active
US8399520 Selective estrogen receptor modulator 25 Dec, 2025
Active


Given below is the list of recent legal activities going on the following drug patents of Stemline Therap.

Activity Date Patent Number
Patent litigations
Email Notification 09 Apr, 2024 US11819480
Mail Pet Dec Routed to Certificate of Corrections Branch 08 Apr, 2024 US11819480
Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Issue 08 Apr, 2024 US11819480
Adjustment of PTA Calculation by PTO 05 Apr, 2024 US11819480
Pet Dec Routed to Certificate of Corrections Branch 05 Apr, 2024 US11819480
Record a Petition Decision of Granted for Patent Term Adjustment after Issue 05 Apr, 2024 US11819480
Second letter to regulating agency to determine regulatory review period 08 Feb, 2024 US10071066
Second letter to regulating agency to determine regulatory review period 08 Feb, 2024 US8399520
Second letter to regulating agency to determine regulatory review period 08 Feb, 2024 US10420734
Second letter to regulating agency to determine regulatory review period 08 Feb, 2024 US7612114
Payment of Maintenance Fee, 4th Year, Large Entity 31 Jan, 2024 US10745343
Letter from FDA or Dept of Agriculture re PTE application 30 Jan, 2024 US7612114
Letter from FDA or Dept of Agriculture re PTE application 30 Jan, 2024 US8399520
Letter from FDA or Dept of Agriculture re PTE application 30 Jan, 2024 US10071066
Letter from FDA or Dept of Agriculture re PTE application 30 Jan, 2024 US10420734


Stemline Therap's Family Patents

Stemline Therap drugs have patent protection in a total of 17 countries. It's US patent count contributes only to 41.5% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents



Stemline Therap Drug List

Given below is the complete list of Stemline Therap's drugs and the patents protecting them.


1. Orserdu

Orserdu is protected by 8 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10385008 Polymorphic forms of RAD1901-2HCL 05 Jan, 2038
(13 years from now)
Active
US10745343 Polymorphic forms of RAD1901-2HCl 05 Jan, 2038
(13 years from now)
Active
US11819480 Methods for treating cancer 29 Nov, 2036
(11 years from now)
Active
US10071066 Method of treating cancer using selective estrogen receptor modulators 10 Oct, 2034
(9 years from now)
Active
US10420734 Method of treating cancer using selective estrogen receptor modulators 10 Oct, 2034
(9 years from now)
Active
US11779552 Method of treating cancer using selective estrogen receptor modulators 10 Oct, 2034
(9 years from now)
Active
US7612114 Selective estrogen receptor modulator 18 Aug, 2026
(1 year, 7 months from now)
Active
US8399520 Selective estrogen receptor modulator 25 Dec, 2025
(1 year, 6 days from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orserdu's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List